A Primer on Radiopharmaceutical Therapy

Salerno, Kilian E.; Roy, Soumyajit; Ribaudo, Cathy; Fisher, Teresa A.; Patel, Ravi B.; Mena, Esther; Escorcia, Freddy E.

doi:10.1016/j.ijrobp.2022.08.010

Cited by 14 publications

(10 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most classic example of use of radionuclide therapy is the application of radioactive iodine in 1941 for the treatment of thyroid disease (10,(43)(44)(45). The capability of 131 I for simultaneous imaging and treatment makes it the first theranostic radiopharmaceutical with 131 I still in use today (46). This approach, also dubbed "theranostics," or the combination of therapeutics and diagnostics with radiopharmaceuticals, is centered on the idea that visualizing the targets can inform the administered activity for therapy.…”

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

“…Whether the theranostic pharma- Notes. Summarizes selected radiopharmaceuticals currently FDA approved for clinical use (46). *Refers to drugs that are not currently commercially available, mCRPC (metastatic castration resistant prostate cancer).…”

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

“…Several techniques have been developed including peptide receptor radionuclide therapy (PRRT), which uses peptides conjugated to isotopes to target site specific delivery of radiation (56). This form of radiopharmaceutical therapy is the most successful to date and targets receptors specific to certain tumor types including the somatostatin receptors (SSTRs) and prostate specific membrane antigen (PSMA) (46). FDA approval of Somatostatin analogs 68 Ga-DOTATATE and 177 Lu-DOTATATE and several radionuclides targeting PSMA expressing cancers have driven efforts to develop other radiopharmaceuticals.…”

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

See 2 more Smart Citations

The Future of Radioactive Medicine

et al. 2023

View full text Add to dashboard Cite

The discovery of X rays in the late 19th century heralded the beginning of a new age in medicine, and the advent of channeling the power of radiation to diagnose and treat human disease. Radiation has been leveraged in medicine in a multitude of ways and is a critical element of cancer care including screening, diagnosis, surveillance, and interventional treatments. Modern radiotherapy techniques include a multitude of methodologies utilizing both externally and internally delivered radiation from a variety of approaches. This review provides a comprehensive overview of contemporary radiotherapy methodologies, the field of radiopharmaceuticals and theranostics, effects of low dose radiation and highlights the phenomena of fear of exposure to radiation and its impact in modern medicine.

show abstract

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

Section: Radiopharmaceuticals and The Advent Of Modern Theranosticsmentioning

confidence: 99%

See 1 more Smart Citation

The Future of Radioactive Medicine

et al. 2023

View full text Add to dashboard Cite

show abstract

“…4,5 The inherent physical properties of the radioligand and the pharmacology of the targeting vector will govern the utility of each specific RPT agent. 6 Novel targets and vectors, as well as novel α-emitting agents, along with normal tissue safeguarding, can mitigate these issues and further refine RPT, ensuring that this remarkable treatment evolves to match patient and provider needs.…”

mentioning

confidence: 99%

“…In addition, biological questions still need to be addressed such as continued off-target toxicity and subtotal cell killing, suboptimal delivery of drug to target, tumor and receptor expression heterogeneity, and radiosensitivity 4,5 . The inherent physical properties of the radioligand and the pharmacology of the targeting vector will govern the utility of each specific RPT agent 6 . Novel targets and vectors, as well as novel α-emitting agents, along with normal tissue safeguarding, can mitigate these issues and further refine RPT, ensuring that this remarkable treatment evolves to match patient and provider needs.…”

mentioning

confidence: 99%

Radiopharmaceuticals for Cancer Diagnosis and Therapy

Taunk,

Escorcia,

Lewis

et al. 2024

Cancer J

Self Cite

View full text Add to dashboard Cite

Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies, peptides, or small molecules has expanded the scope of radiopharmaceutical therapy, enabling precise and effective cancer treatment for an increasing number of tumor types. Alpha emitters, characterized by their high linear energy transfer and short path length, offer unique advantages in targeted therapy due to their potent cytotoxicity against cancer cells while sparing healthy tissues. This article reviews recent advancements in identifying novel targets for radiopharmaceutical therapy and applications in utilizing α-emitters for targeted treatment.

show abstract

CAR T-cells for pediatric solid tumors: where to go from here?

Trautmann,

Yakobian,

Nguyen

2024

Cancer Metastasis Rev

View full text Add to dashboard Cite

Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors. Especially in the pediatric population, pre- and post-treatment biopsies are rarely performed due to ethical reasons, and thus, our understanding is still very limited regarding the mechanisms in the tumor microenvironment by which tumor cells exclude effectors and attract immune-suppressive cells. Nevertheless, based on the principles that are known, current T-cell engineering has leveraged some of these processes and created more potent CAR T-cells. The recent discovery of new oncofetal antigens and progress made in CAR design have expanded the potential pool of candidate antigens for therapeutic development. The most promising approaches to enhance CAR T-cells are novel CAR gating strategies, creative ways of cytokine delivery to the TME without enhancing systemic toxicity, and hijacking the chemokine axis of tumors for migratory purposes. With these new modifications, the next step in the era of CAR T-cell development will be the clinical validation of these promising preclinical findings.

show abstract

A Primer on Radiopharmaceutical Therapy

Cited by 14 publications

References 63 publications

The Future of Radioactive Medicine

The Future of Radioactive Medicine

Radiopharmaceuticals for Cancer Diagnosis and Therapy

CAR T-cells for pediatric solid tumors: where to go from here?

Contact Info

Product

Resources

About